{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:49:59Z","timestamp":1777420199596,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fluoroquinolones (FQs) are associated with increased risk of tendon injury but comparative risk versus other antibiotic options for the same indication has yet to be evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Describe the incidence (relative risk) of any tendon injury in patients receiving FQ compared with other (non-FQs) antibiotics for treatment of community-acquired pneumonia (CAP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective propensity score weighted cohort study was performed to evaluate the association between FQ antibiotics and tendon injury risk at 2 time points (within 1 month and within 6 months of use) compared with non-FQ regimens for treatment of CAP. The evaluation was performed using the CCAE (MarketScan Commercial Claims and Encounters) and COB (Medicare Supplemental and Coordination of Benefits) databases from 2014 to 2020. Patients with ICD (International Classification of Diseases) 9\/10 coding for outpatient pneumonia who were &gt;18 years and without history of tendon injury were included. Patients with history of tendon injury, who received multiple antibiotic therapies for recurrent pneumonia, or who received both FQ and non-FQ regimens during the study period were excluded. Propensity score weighting was used to adjust for selection bias due to contributing risk factors, including demographics (age, sex), comorbidities (diabetes mellitus, chronic kidney disease), and concurrent medications (corticosteroids).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At 1 month, the odds of tendon injury were estimated to be significantly higher (41.9%) in patients receiving FQs compared with those receiving a non-FQ-based regimen (odds ratio [OR] = 1.419, 95% confidence interval [CI] = [1.188-1.698]). The odds of tendon injury were also estimated to be higher (OR = 1.067, 95% CI = [0.975-1.173]) in the FQ population within 180 days, but this effect was not statistically significant. The most frequent sites of tendon injuries were rotator cuff, shoulder, and patellar tendon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance:<\/jats:title>\n                    <jats:p>Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231210275","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:43:52Z","timestamp":1699577032000},"page":"771-780","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6826-8711","authenticated-orcid":false,"given":"Virginia H.","family":"Fleming","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Georgia, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Georgia, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Georgia, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Georgia, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Southwood","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Georgia, Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"bibr1-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"bibr2-10600280231210275","unstructured":"US Food and Drug Administration. Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Drugs, Drug Safety and Availability Postmarket Drug Safety Information for Patients and Providers Web site. Accessed May 14, 2023. http:\/\/wayback.archive-it.org\/7993\/20161022101528\/http:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126085.htm"},{"key":"bibr3-10600280231210275","unstructured":"Food and Drug Administration. Information for Healthcare Professionals: \u201cFDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together.\u201d. Drugs, Drug Safety and Availability Postmarket Drug Safety Information for Patients and Providers Web site. Accessed May 14, 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics"},{"key":"bibr4-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2841"},{"key":"bibr5-10600280231210275","unstructured":"Measuring Outpatient Antibiotic Prescribing. Updated 2021. Accessed September 26, 2023. https:\/\/www.cdc.gov\/antibiotic-use\/data\/outpatient-prescribing\/index.html"},{"key":"bibr6-10600280231210275","unstructured":"Anderson LA. Antibiotic guide. Accessed August 26, 2023. https:\/\/www.drugs.com\/article\/antibiotics.html"},{"key":"bibr7-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1761"},{"key":"bibr8-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1086\/375078"},{"key":"bibr9-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0089-8"},{"key":"bibr10-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00828-z"},{"key":"bibr11-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0729-y"},{"key":"bibr12-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034844"},{"key":"bibr13-10600280231210275","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.814333"},{"key":"bibr14-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2162"},{"key":"bibr15-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-033316"},{"key":"bibr16-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.05.027"},{"key":"bibr17-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02713-1"},{"key":"bibr18-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1214"},{"key":"bibr19-10600280231210275","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629100-00006"},{"key":"bibr20-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7349.1306"},{"key":"bibr21-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.15.1801"},{"key":"bibr22-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0265-9"},{"key":"bibr23-10600280231210275","unstructured":"Centers for Disease Control. ICD-9 code look up. Accessed December 4, 2022. https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm"},{"key":"bibr24-10600280231210275","unstructured":"Centers for Disease Control. ICD-10 code look up. Accessed December 4, 2022. https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm.htm"},{"key":"bibr25-10600280231210275","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws412"},{"key":"bibr26-10600280231210275","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2005.10314"},{"key":"bibr27-10600280231210275","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. Updated 2021. Accessed December 5, 2023. https:\/\/wwwR-project.org\/"},{"key":"bibr28-10600280231210275","unstructured":"Noah Greifer. WeightIt software- weightIt: weighting for covariate balance in observational studies. R package version 0.13.1. Accessed December 4, 2022. https:\/\/CRAN.R-project.org\/package=WeightIt"},{"key":"bibr29-10600280231210275","unstructured":"Noah Greifer. cobalt: covariate balance tables and plots. R package version 4.4.0. Accessed December 4, 2022. https:\/\/CRAN.R-project.org\/package=WeightIt Web site. https:\/\/CRAN.R-project.org\/package=cobalt"},{"key":"bibr30-10600280231210275","unstructured":"Canty AaR, Brian. boot: Bootstrap R (S-Plus) Functions. R package version 1.3-28. boot: Bootstrap Functions (Originally by Angelo Canty for S) web site. Updated 2021. Accessed December 4, 2022. https:\/\/cran.r-project.org\/web\/packages\/boot\/index.html"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231210275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231210275","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231210275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:25Z","timestamp":1777374805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231210275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1177\/10600280231210275"],"URL":"https:\/\/doi.org\/10.1177\/10600280231210275","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}